Last reviewed · How we verify
Drysol
Drysol is a Small molecule drug developed by Northwestern University. It is currently in Phase 1 development.
Drysol, a product containing Aluminum Chloride 20%, is used to treat hyperhidrosis. Aluminum Chloride 20% is a topical treatment that is also studied in clinical trials for other conditions such as residual limb hyperhidrosis.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Drysol |
|---|---|
| Sponsor | Northwestern University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Clinical Evaluation of Metal Panel Allergens: Mercury, Aluminum and Palladium Dose Response Study (Phase 2)
- Prospective Multicentric Open Randomised Controlled Trial Comparing Topical Aluminium Chloride to OnabotulinumtoxinA Intradermal Injections in Residual Limb Hyperhidrosis (Lower Limbs) (Phase 3)
- Comparison of Effectiveness of Gingival Displacement Using Retraction Cord and Aluminum Chloride Gel (Phase 4)
- Hyperhidrosis of the Residual Limb in Patients With Amputations: Developing a Treatment Approach (Phase 1)
- Non-prescription Versus Prescription Topical Treatments Versus no Treatment in the Control of Sweating (NA)
- Hyperhidrosis of the Residual Limb in Patients With Amputations: Developing a Treatment Approach, Aims 1 and Aim 2 (Phase 1)
- Antiperspirant in the Treatment of Residual Limp Hyperhidrosis for Prosthetic Users: a Pilot Study (NA)
- Clinical Evaluation of Different Gingival Displacement Methods (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Drysol CI brief — competitive landscape report
- Drysol updates RSS · CI watch RSS
- Northwestern University portfolio CI
Frequently asked questions about Drysol
What is Drysol?
Who makes Drysol?
What development phase is Drysol in?
Related
- Manufacturer: Northwestern University — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing